相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Psoriasis triggered by infliximab in a patient with Behcet's disease
Yuko Kawazoe et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2013)
Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease
Hiroshi Goto
ARCHIVES OF OPHTHALMOLOGY (2012)
Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy
Atsushi Yoshida et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2012)
Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy
Hiroshi Keino et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2011)
Induction of Regulatory T Cells by Infliximab in Behcet's Disease
Sunao Sugita et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease
Yukiko Yamada et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
Regression of Optic Disc Neovascularization in Patients with Behcet's Uveoretinitis After Infliximab Therapy
Tatsushi Kawaguchi et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions
Alfredo Adán et al.
INTERNATIONAL OPHTHALMOLOGY (2010)
Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up
Renato Caviglia et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study
L. Niccoli et al.
RHEUMATOLOGY (2007)
Infliximab treatment for ocular and extraocular manifestations of Behcet's disease
Massimo Accorinti et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2007)
Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β
Suchita Nadkarni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Intraocular cytokine environment in active Behcet uveitis
Jae Kyoun Ahn et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2006)
Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement
M Takeuchi et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2005)
Infections in patients with rheumatoid arthritis treated with biologic agents
J Listing et al.
ARTHRITIS AND RHEUMATISM (2005)
Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease -: An open-label trial
I Tugal-Tutkun et al.
ARTHRITIS AND RHEUMATISM (2005)
Psoriasis induced by anti-tumor necrosis factor therapy - A paradoxical adverse reaction
PP Sfikakis et al.
ARTHRITIS AND RHEUMATISM (2005)
A prospective trial of infliximab therapy for refractory uveitis - Preliminary safety and efficacy outcomes
EB Suhler et al.
ARCHIVES OF OPHTHALMOLOGY (2005)
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
M De Bandt et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
X Baraliakos et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal - Results from a twelve-month randomized, double-blind, placebo-controlled trial
MA Quinn et al.
ARTHRITIS AND RHEUMATISM (2005)
Uveitis in Behcet disease: An analysis of 880 patients.
I Tugal-Tutkun et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2004)
Anti-tumor necrosis factor therapy and Listeria monocytogenes infection:: report of two cases
T Glück et al.
ARTHRITIS AND RHEUMATISM (2002)
Miliary tuberculosis after biological therapy for rheumatoid arthritis
PR Querini et al.
RHEUMATOLOGY (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)